Clearline Capital’s Stemline Therapeutics, Inc. STML Stock Holding History

Clearline Capital’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,519,843	Closed	-$7.36M	–	96
2020 Q1	$7.36M	Buy	1,519,843 +1,067,714	+236%	+$6.92M	3.4%	8
2019 Q4	$4.81M	Buy	452,129 +145,364	+47%	+$1.44M	2.06%	16
2019 Q3	$3.19M	Buy	306,765 +154,924	+102%	+$2.03M	1.45%	23
2019 Q2	$2.33M	Sell	151,841 -27,239	-15%	-$394K	1.14%	31
2019 Q1	$2.3M	Buy	+179,080	New	+$2.02M	1.2%	26

Clearline Capital's STML Position: Q2 2020 in Review

Clearline Capital sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 1,519,843 shares — an estimated $7.36M sold.

Clearline Capital first reported a position in STML in Q1 2019 and held it in 5 quarters. The position peaked at $7.36M in Q1 2020. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.

Clearline Capital reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
Clearline Capital sold 1,519,843 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $7.36M.
Clearline Capital first reported a position in Stemline Therapeutics, Inc. in Q1 2019 and held it in 5 quarters.
Clearline Capital's Stemline Therapeutics, Inc. position peaked at $7.36M in Q1 2020.
0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.

Based on Clearline Capital's 13F filing for Q2 2020, filed 14 Aug 2020.